Several epidemiologic studies have reported lower circulating natriuretic peptide concentrations in obese individuals.12, 14 However, these studies have been observational and confined to a single time point of measurement of natriuretic peptides. To our knowledge, only one previous study has examined the association of obesity with salt‐induced natriuretic peptide concentrations. Licata and colleagues found reduced, salt‐loaded plasma ANP concentrations in 9 obese individuals compared with 10 lean controls.21 They did not examine the influence of weight loss on the natriuretic peptide system. Thus, the present study is the first to provide serial, physiologic data from the same individuals over time.

For GH to exhibit its fat burning effects, insulin must NOT be present. Insulin release in the body is caused mainly by consuming carbohydrates, although all types of macronutrients (carbs, fat and protein) still cause the release of insulin to some extent. Since HGH Frag works by causing the body to break down and release stored fat for use as energy, if you have recently consumed calories (food or beverage) your body will just use that for energy instead and little extra fat will be burnt. If however there is no food present for the body to use as energy, it will use the stored fat which the HGH Frag has caused to be released and you will notice reductions in body fat over the ensuing weeks.
Wow you are really thick arnt you... ok lets call it a drug if it floats your boat... if you bothered to actually understand how it works you would probably have an enlightning moment as to why itssuch a debatable comment... its a peptide a very complex string that stimulates the p gland... the p gland that creates GH stimulation from our own body... it has nothing to do with being a varient of gh like YOUR FACTS state... this is why its under SO and arguable as a PED... do you even know what an amino acid chain is...? Obviously not...
The duration (treatment and follow up) of the individual studies depended on the type of study (supplementary data). The first three clinical trials were single dose treatments (METAOD001 - METAOD003); the longest was a phase IIb clinical trial (METAOD006) with a four weeks run-in phase, followed by a six months treatment phase and a 30 day follow-up phase.
The expression of β3-AR RNA was assessed by RT by using radiolabeled primers and Southern blot analysis. Labeled bands were identified and semiquantitated by phosphorimaging. RT-PCR analysis demonstrated that ob/ob mice express lower amounts ofβ 3-AR RNA in their white (Fig. 3A) and brown (Fig. 3B) adipose tissues, compared with lean C57BL/6J mice, in agreement with others (14). Figure 3A shows the effect of saline, AOD9604, and hGH on β3-AR RNA expression in epididymal adipose tissue from both lean and obese mice, respectively. The level of β3-AR expression increased significantly in response to AOD9604 and hGH only in the obese mice, correlating with the significant decrease in epididymal adipose tissue weights seen in these mice. The same correlation was observed in brown adipose tissue, where increased expression of β3-AR was accompanied by a decrease in brown adipose tissue mass in both lean and obese mice (Fig. 3B).
As women age, the #1 reason for weight gain is hormonal imbalance. In fact, hormonal imbalance can lead to unwanted adult acne, loss of sexual desire, and sagging breasts. When you correct this imbalance, you begin to lose body fat, overcome acne, naturally lift and enhance breast tissue, and improve libido! OxySelect Pink was formulated for women by women, and the results are incredible and comes with a 100% money-back guarantee! Read More
One proposed mechanism for reduced natriuretic peptide concentrations in obesity is the relative abundance of natriuretic peptide clearance receptors (NPR‐C) in adipose tissue.13, 22 Elevated insulin has also been linked to increased expression of NPR‐C in obese subjects.23 On the other hand, plasma Nt‐proANP and Nt‐proBNP levels are reduced in obesity to a comparable degree as the mature peptides. Because the pro‐peptides are not known to bind to NPR‐C, impaired synthesis or secretion likely plays a role in obesity.
As an athlete, you can also increase your dosage cycle for a period of 12 to 16 weeks at a time, to maximize your gains. Do so gradually if you opt to go this route. Make sure you increase your daily dosage (1 to 2 doses per day, etc.) gradually. Start off with lower dosage levels as well, and see how it interacts with your body. You don’t want to experience withdrawal, nor do you want to experience negative side effects when using Ipamorelin for longer dosage cycles. So, make sure you monitor your progress, see how you feel as you go, and make notes if/when you do experience negative side effects, so you can balance down to the proper dosage levels.
A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. Daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days reduced over 50% (15.8 +/- 0.6 vs. 35.6 +/- 0.8 g) body weight gain of the animals in comparison with the control. The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic activity. In contrast to chronic treatment with intact hGH, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques. The results in the present study suggest that the analogue of the hGH lipolytic domain may have the potential to be developed into an orally usable and safe therapeutic agent for obesity.

Human Growth Hormone (hGH) is not only important for growth processes during childhood, but plays a pivotal role in lipid metabolism throughout life. It is well known that hGH is involved in the regulation of lipolysis and lipogenesis. Therefore, hGH was implicated as a good potential candidate for the treatment of obesity. However undesired side effects, such as induction of glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13] rendered therapeutic doses of hGH unsuitable for long-term treatments in humans.
In 2010, the company heard word that bodybuilders were importing knock-off versions of the patent-protected peptide from China, and started licensing the manufacturing rights out to other companies in an attempt to compete, as this was determined to be a better course of action than attempting to sue the Chinese company for patent breach (7, 8). Desperate to recoup this investment, they invested a small additional amount into developing a technology that allowed the peptide to be absorbed through the skin, in collaboration with a company called Phosphagenics (4). The peptide was then licensed for use in BodyShaper, an anti-cellulite cream. Phosphagenics later dropped AOD9604 from BodyShaper, citing excessive expense and ineffectiveness (3).
Five public submissions were received. Many of the submissions referred to the article published in the New England Journal of Medicine (NEJM) when giving their reasons for either supporting or rejecting the proposal. Some submissions also noted that a similar proposal is to be considered by an upcoming meeting of the Medicines Classification Committee (MCC) in New Zealand.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
The amazing effects of HCG on the hypothalamus were discovered by Dr. Albert T. W. Simeons in 1954, who observed that malnourished women tend to give birth to healthy babies with normal birth weights. Dr. Simeons concluded that women are able to do this because the HCG hormone that their bodies naturally produced during pregnancy helped their bodies to metabolise subcutaneous fat. hCG released by the embryo also helps women with weight redistribution (helps prevent uneven deposits of weight on thighs, abdomen, hips etc) and therefore women concerned with hormonal weight gain are ideal candidates for this diet.
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”

Metabolic Pharmaceuticals have reported that recent in vitro trials have shown that AOD9604 may stimulate the growth of bone cells, and muscle and cartilage cells. These results have not yet been reproduced in animals or humans (4). There was a lot of speculation that Metabolic was providing AOD9604 to players at the Essendon Football Club as part of a secret clinical trial, but the company has flatly denied this claim, claiming it has not run any human trials since 2007 (2). AOD9604 has been scientifically proven safe and side-effect free (2), and is apparently very difficult to detect in the blood.

There’s never been a better formula to help you reach your weight loss goals with patented, clinically-proven, and all-natural ingredients. While being one of the most powerful formulas on the market, it’s the safest as well. The best part is each and every bottle is backed by a 90-day, 100% Money Back Guarantee, making Apidren completely RISK FREE! With these clinically proven ingredients and industry-leading money back guarantee, there’s no other diet supplement we would recommend! Read More
Osteoarthritis (OA) is a degenerative joint disease that results from articular cartilage loss induced by complex interactions of genetic, metabolic, biochemical, and biomechanical factors with secondary components of inflammation [1]. OA is the most common arthritis and a major medical problem in people aged 65 years and older [2]. Non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, exercises, corticosteroids, and hyaluronic acid injections have all been used for the conservative treatment of OA. The role of NSAIDs in OA management is controversial because of its adverse side effects, as well as side effects on the cartilage [3].

This duration is a sufficient time to allow the ghrelin peptide to work through your system, and also for it to have a long lasting effect with continued use. It will work to enhance the hormone system, increase the metabolic rate, and increase lean muscle tissue levels in this period of time. As discussed above, the proper dosage for new users is 200 to 300 mcg daily, at the same time each day. For more experienced users, you can take the same dosage, 2 to 3 times a day (remember that it is the same time each day, and is best to use your injection after a meal for the best results possible).


Echocardiograms were performed before and after saline infusion at both the baseline and post‐gastric bypass surgery visits. Each subject had four echocardiograms in total during the entire study. Interpretations were made by investigators blinded to clinical status (before or after saline infusion, before or after surgery). The following standard measures were made on two‐dimensional (2D) images in each echocardiogram: interventricular septal and posterior wall thickness (IVS and PWT), left ventricular internal diameter at end‐diastole and end‐systole (LVID, LVIS) and left atrial anteroposterior diameter (LA Dia) in the parasternal view, left ventricular (LV) volumes using a modified Simpson's rule (apical 4 chamber and 2 chamber views), mitral inflow E and A velocities and E deceleration time, and mitral annular early diastolic (e′) velocity at the lateral annulus. We did not calculate left atrial volumes due to limited echocardiographic windows in severely obese patients. Estimation of left atrial filling pressure was obtained every 20 minutes during the second hour of the infusion by determining the ratio of the early diastolic mitral inflow velocity to the early diastolic mitral annular velocity.15

Peptides are defined as a compound of two or more amino acids in which a carboxyl group of one is united with an amino group of another. With the elimination of a water molecule, a peptide bond is formed. To put it more simply, peptides are just small proteins. When the number of amino acids are less than 50, these are peptides. When higher than 50, these are proteins. The peptides are therefore small chains of amino acid which are present in all cells of the body. There are several kinds of peptides: oligopeptides, polymers, proteins, neuropeptides and peptide hormones. These are synthesized naturally by the body. Peptides will therefore be used primarily to make a more abundant amount of hormones in the body. The latter will then produce new hormones such as Testosterone or corticosteroids. It is these two hormones that are considered anabolic or indirect anti-inflammatory.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (beta(3)-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.
LR3 would be great for fatloss. I would use that solo (not with cjcdac or gh)... obviously if you have any clen, t3, eca etc then you could add them in. I have limited experience with lr3 so can't fully comment from my own research. But from what I observed on Bane it is great for fatloss... anything that raises igf-1 should be. But the results from the cjc-dac were superior in every way during my research.

The weight lost by the 1mg group was slightly more than that achieved by the world’s largest selling prescription obesity medication in similar trials over the same period, without its troublesome side effects. The trial results also demonstrated a small but consistent improvement in cholesterol profiles, and a reduction in the number of patients with impaired glucose tolerance.


I can't believe we as Aussies are the 1st to point the finger of other countries on drug cheats, as soon as its in our own backyard and one of our afl footy teams, we seem to downplay the seriousness of drugs in sport, its crazy, and to think they didnt know what was being injected, doh. my favorite is the Shane Warne Diuretics that his mum gave him, lol, 12 month ban, Essendon minimum 2 year ban.....has to be.
Whilst not illegal to buy AOD9604 in Australia, AOD9604 does not have approval by the TGA, which means it is not allowed to be sold on the basis of it having any pharmaceutical or performance enhancing benefits. It has not been approved by any pharmaceutical authority worldwide, except for the previously mentioned "Generally Regarded As Safe" designation by the FDA. AOD9604 is currently classed by the World Anti Doping Agency (WADA) as a non-approved substance, which means it is not legal for use by athletes in competition. WADA policy is to ban all substances that are suspected of being performance-enhancing, even in the absence of clinical proof (1,2).
It has to be noted that three of the SAEs were skin cancer forms. Since the study was performed in Australia, a country with the highest incidence rate of skin cancer (http://globocan.iarc.fr/), this cumulative incidence is not improbable. Furthermore the study was performed on clinically obese subjects with a BMI ≥ 35 kg/m2 (BMI ≥ 35 kg/m2; Median BMI: 40 kg/m2, range: 35 to 67 kg/m2). It is known that the incidence of several types of cancers is associated with increased BMI [26].
Muscle Peptides Australia strived to provide the highest quality peptide supplements available. Our research and development team work constantly to develop exclusive products that consistently outperform other supplements and brands on the market. We’ve specifically designed our products to assist in weight loss, muscle gain and increase injury recovery rates. Read more about what makes Muscle Peptides Australia the industry leaders in peptide supplements.
To put this into simple terms, collagen protein promotes fullness and keeps our body feeling satisfied after a meal. If we feel more full for a longer time after eating, we are less likely to overeat at the next meal. This goes hand in hand with fighting off pesky cravings. We know how difficult it can be to fight cravings, such as those for salty, oily or fatty foods. And not to mention sugary foods, which our brain can actually get addicted to. Including collagen into your daily diet can help in the battle against cravings and weight loss by keeping you full and satisfied.
AOD9604: AOD9604 is a synthetic peptide taken orally. The small peptide mimics a section of the growth hormone molecule which increases fat metabolism and decreases the production of fat. AOD9604 is claimed to reduce fat, increase muscle mass and possibly help recover from joint cartilage damage. However, there is currently no published human data to support these claims. AOD9604 is not approved for human use, but is used in sport for weight loss and muscle enhancement and the perception that it helps recover from tissue damage. This drug was highlighted in the Australian Crime Commission report on Organised Crime and Drugs in Sport. No significant adverse effects have been reported yet, but AOD9604 is now prohibited by WADA.

The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.
All studies were performed as double-blind placebo-controlled trials with specific design adaption depending on the question that was to be answered. All, but the first, were performed on obese, but otherwise healthy, adults. In the first 4 studies, only male subjects were included (supplementary data). Approximately 900 adult subjects participated in these 6 clinical trials.

Within all the clinical trials the subjects received either the active treatment AOD9604 Tyr-hGH177-191(Metabolic Pharmaceuticals Ltd.; amino acid sequence: YLRIVQCRSVEGSCGF; CAS Registry Number: 38624-39-7; INCI Name: 27701 sh-Oligopeptide-74) or placebo (vehicle of mix of excipients). In addition, in study METAOD001 individual subjects were treated with rhHG (0.12 IU/kg; supplied by Unichem in the form of somatropin (Saizen® - Serono)) as a positive control. The administered doses of the study product ranged from 25 µg up to 400 µg per kg bodyweight for the injectable product (i.v. administration in study METAOD001 and METAOD002) and from 0.25 mg/day to 54 mg/day for the orally administered capsules/tablets (capsules METAOD003 - METAOD005; tablets: METAOD006).


David Kenley - holds a 6.9% interest in Calzada Ltd, which fully owns Metabolic Pharmaceuticals Pty Ltd. Evert Vos - is a Consultant to Metabolic Pharmaceuticals Pty Ltd. He was previously the Medical Director of the company responsible for all of the human clinical trials. Heike Stier is an employee of analyze and realize ag and has written this manuscript. Analyze and realize ag acts as an consultant to Metabolic Pharmaceuticals Pty Ltd in relation to possible novel food applications in the European region.
No need to visit a physical peptide clinic, Muscle Peptide Australia can ship throughout Australia: to Sydney, Melbourne, Brisbane, Perth, Adelaide, Darwin, Hobart and regional areas. There’s no time like now to begin this journey. Customers can order from our convenient and user-friendly website to get the supplements they need. Send us an e-mail, and our customer service team will be happy to address any questions or concerns you may have. We specialize in offering an affordable and efficient way to stay healthy for good.
×